Researchers from the University of Texas / MD Anderson Cancer Center published an interesting recent study in the journal Cancer on the treatment and assessment of so-called neoadjuvant therapy in borderline resectable pancreatic cancer (ductal adenocarcinoma of the pancreas).
“Neoadjuvant” is a word that denotes typically the medical and/or radiological treatment of pancreatic cancer BEFORE surgery. The term “adjuvant” refers typically to the medical and/or radiological treatment of pancreatic cancer AFTER surgery.
As those patients who are eligible and receive the surgery option for pancreatic cancer tend to do better than those who are not so eligible, it has seemed logical to see if there are ways to increase the number of patients who are eligible for surgery.
The physicians at MD Anderson Cancer Center (and other noted institutions) have been at the forefront of giving this neoadjuvant therapy – to see if there will be a radiologic response such that some percentage of those previously not eligible for surgery – would now be. And further, if they now are finally eligible for surgery – do these patients do as well as those who were eligible from the beginning? (It appears, with caveats – that they tend to do as well).
The UNEXPECTED finding reported out in this study is different, however ! The researchers looked at 129 patients who met criteria from 2005 until 2010 at their institution. They found that although 69% of those patients with borderline surgical criteria who had received neoadjuvant therapy underwent surgery, only 1% had had their disease downstaged to resectable by radiological standards.
They then looked at outcomes and found that those who had received the surgery tended to live longer.
The rather astounding conclusion is that borderline resectable patients treated with neoadjuvant therapy without subsequent radiological evidence of downstaging should probably receive surgery anyway, in the absence of metastases.
This important conclusion will need to be substantiated by further studies.
Dale O’Brien, MD